Recent Pharmaceuticals press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

1

[PRESSWIRE] Austria - 24 September, 2020 -- Eveliqure Biotechnologies GmbH, an Austrian biotechnology company, today announces the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity study in Europe.

1

[PRESSWIRE] US - 19 September, 2020 - B Medical Systems, a leading European medical refrigeration and global vaccine cold chain manufacturer, is pleased to announce the official opening of its new 10,000 sq ft sales office and warehouse in Noblesville, Indiana. With over 40 years of experience in the medical refrigeration and vaccine cold chain market, the company offers a full line of medical-grade refrigerators, freezers, ultra-low temperature freezers, and transport devices designed for the safe storage and transport of biological materials, critical samples, blood, and vaccines.

1

[PRESSWIRE] Israel - 13 August, 2020 -- Kanabo Research LTD und Simply Green BV haben eine exklusive Vertriebsvereinbarung unterzeichnet, um die medizinische Verdampfungstechnologie von Kanabo auf den deutschen Markt zu bringen. Im Rahmen der Vereinbarung erhält Simply Green das exklusive Vertriebsrecht für die proprietäre Lieferplattform Kanabo VapePod® und Rezepturen über dessen Vertriebsnetz.

1

[PRESSWIRE] London, United Kingdom - 13 August, 2020 -- Global liquidation specialists Maynards Europe and Liquidity Services are to sell the complete contents of Recipharm’s Ashton-under-Lyme pharmaceutical facility by online auction on October 22. The project will include logistics partners offering turnkey solutions to relocate and recommission equipment globally.

1

[PRESSWIRE] Vienna - 30th June 2020 -- Eveliqure Biotechnologies today announces that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total investment provided by Arax. This is complemented by further private investment from Baobá and a Swiss based family office, and totals around €0.5M.

1

[PRESSWIRE] Vienna - 4 June, 2020 -- The Austrian biotech company CEBINA GmbH announces that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic. This seed funding will support proof-of-concept studies of the vaccine that will allow progress to pre-clinical development, scheduled for Q1/2021. The funds are provided by the Blom Family Office.

1

[PRESSWIRE] Vienna - 2nd June 2020 -- Eveliqure Biotechnologies today, announces that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent diarrhoeal diseases caused by Shigella and Enterotoxigenic E. coli (ETEC).  

[PRESSWIRE] Frankfurt a. M., Germany & Haarlem, The Netherlands - 17 May, 2020 -- FIZ (Frankfurt Biotechnology Innovation Center GmbH) and Sri Sri Tattva Europe B.V. collaborate to fight against COVID-19 through Ayurveda.

1

[PRESSWIRE] Luxembourg - 14 May, 2020 -- The pandemic has taken the medical world by surprise and challenged the medical device industry, putting a heavy strain on manufacturers. How does a CEO juggle between the intensifying demand for reliable medical equipment, the need for innovations, and the safety of his employees to make sure that COVID-19 is behind us in the shortest time possible?

1

[PRESSWIRE] Austria - 20 April, 2020 -- Austrian biotech company Calyxha Biotechnologies GmbH is pleased to announce the grant of European Patent No. EP3383381. This patent covers the use of calixarene compounds for neurodegenerative diseases, including Parkinson’s disease. It represents the company’s first granted patent, with prosecution of the corresponding patent applications ongoing in other territories.